Federal contract award
HHSO100201000035C
TAS::75 0140::TAS CLINICAL TRIAL IN A TEST TUBE FOR MEDICAL COUNTERMEASURE DEVELOPMENT
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541711 |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $16.9M |
| Current contract value | $16.9M |
| Potential contract value / ceiling | $26.5M |
| Start date | Jul 30, 2010 |
| Current end date | Sep 29, 2020 |
| Potential end date | Sep 29, 2020 |
| Latest award activity | Aug 19, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 17 of 17 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 19, 2026 | P00016 | $-14.4K | CLINICAL TRIAL IN A TEST TUBE FOR MEDICAL COUNTERMEASURE DEVELOPMENT |
| Sep 20, 2019 | P00015 | $240.8K | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE FUNDING TO COVER INDIRECT RATES ADJUSTMENT FOR FY15 AND FY16 IN SUPPORT OF THE CLINICAL TRIAL IN A TEST TUBE FOR MEDICAL COUNTERMEASURE |
| Sep 19, 2018 | 14 | $-393.5K | THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE $398,471.28 AS PART OF CLOSEOUT PROCEDURES. |
| Sep 29, 2015 | 13 | $0 | EXTEND THE END DATE OF THE CONTRACT TO 1/31/16 AT NO ADDITIONAL COST. |
| Feb 9, 2015 | 12 | $0 | REVISED SOW INCORPORATE CHANGES TO OPTION 2. THERE WILL BE NO ADDITIONAL COST AND THE PERIOD OF PERFORMANCE IS EXTENDED TO 10/31/2015. |
| Jan 5, 2015 | 11 | $0 | REVISED SOW TO BEGIN WORK ON THE LABORATORY PORTION OF THE OPTION FOLLOWING A DELAYED MEETING WITH THE FDA. THERE WILL BE NO ADDITIONAL COST AND THE PERIOD OF PERFORMANCR REMAINS UNCHANGED. |
| May 15, 2014 | 10 | $0 | REVISED SOW TO BEGIN WORK ON THE LABORATORY PORTION OF THE OPTION FOLLOWING A DELAYED MEETING WITH THE FDA. THERE WILL BE NO ADDITIONAL COST AND THE PERIOD OF PERFORMANCR REMAINS UNCHANGED. |
| Jul 11, 2013 | 9 | $5.3M | NO COST EXTENSION TO FACILITATE THE TIME NEEDED TO COMPLETE MODIFICATION TO EXERCISE OPTION |
| Jun 26, 2013 | 8 | $0 | NO COST EXTENSION TO FACILITATE THE TIME NEEDED TO COMPLETE MODIFICATION TO EXERCISE OPTION |
| Mar 21, 2013 | 7 | $0 | NO COST EXTENSION TO THE VAXDESIGN CONTRACT TO ALLOW FOR MORE ADMINSTRATIVE TIME TO EXECUTE THE OPTION. |
| Nov 21, 2012 | 6 | $0 | CLINICAL TRIAL IN A TEST TUBE FOR MIEDICAL COUNTERMEASURE DEVELOPMENT |
| Jul 25, 2012 | 5 | $0 | CLINICAL TRIAL IN A TEST TUBE FOR MIEDICAL COUNTERMEASURE DEVELOPMENT |
| Aug 30, 2011 | 4 | $4.4M | CLINICAL TRIAL IN A TEST TUBE FOR MIEDICAL COUNTERMEASURE DEVELOPMENT |
| Apr 19, 2011 | 2 | $0 | CLINICAL TRIAL IN A TEST TUBE FOR MIEDICAL COUNTERMEASURE DEVELOPMENT |
| Oct 20, 2010 | 1 | $0 | CLINICAL TRIAL IN A TEST TUBE FOR MIEDICAL COUNTERMEASURE DEVELOPMENT |
| Jul 30, 2010 | 0 | $7.5M | TAS::75 0140::TAS CLINICAL TRIAL IN A TEST TUBE FOR MEDICAL COUNTERMEASURE DEVELOPMENT |
| Jul 30, 2010 | 3 | $0 | CLINICAL TRIAL IN A TEST TUBE FOR MIEDICAL COUNTERMEASURE DEVELOPMENT |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.